Ocugen, Inc. (OCGN)
$
0.93
+0.02 (2.15%)
Key metrics
Financial statements
Free cash flow per share
-0.1779
Market cap
224.8 Million
Price to sales ratio
49.7137
Debt to equity
0.2610
Current ratio
2.6036
Income quality
0.8856
Average inventory
0
ROE
-2.2300
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ocugen, Inc. is a clinical-stage biopharmaceutical company that focuses on developing gene therapies aimed at curing blindness diseases. The company's portfolio includes OCU400, a novel gene therapy candidate designed to restore retinal integrity and function for a variety of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. Additionally, OCU410 serves as a gene therapy candidate targeting the treatment of dry age-related macular degeneration (AMD), while OCU200, a novel fusion protein, is currently in the preclinical development stage for conditions like diabetic macular edema, diabetic retinopathy, and wet AMD. The company reported an income before tax of -$54,054,000.00 showcasing its pre-tax profitability. With an operating income of -$54,757,000.00 Ocugen reflects its earnings from core operations. The total costs and expenses for the company amount to $58,812,000.00 highlighting its overall spending, while the gross profit ratio is 0.51 reflecting the efficiency of the company's production and sales operations. The company achieved a revenue of $4,055,000.00 indicating its niche market focus. Ocugen, Inc. also has strategic partnerships with CanSino Biologics Inc. for gene therapy co-development and manufacturing, and with Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania. The stock is affordable at $0.93 making it suitable for budget-conscious investors. With a high average trading volume of 4,070,720.00 the stock indicates strong liquidity, attracting a broad range of stakeholders. Classified as a small-cap player with a market capitalization of $271,822,455.00 Ocugen is a key contributor in the Biotechnology industry, significantly influencing the overall market landscape. As it belongs to the Healthcare sector, the company plays a vital role in driving innovation and growth within its domain.
Is Ocugen, Inc. (OCGN) a good investment?
Investing in Ocugen, Inc. (OCGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Ocugen, Inc. (OCGN)'s stock forecast?
Analysts predict Ocugen, Inc. stock to fluctuate between $0.52 (low) and $1.98 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ocugen, Inc.'s market capitalization?
As of 2025-05-23, Ocugen, Inc.'s market cap is $271,822,455, based on 292,031,000 outstanding shares.
How does Ocugen, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ocugen, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ocugen, Inc. (OCGN) stock?
To buy Ocugen, Inc. (OCGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for OCGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Ocugen, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ocugen, Inc. stock ever split?
Ocugen, Inc.'s last stock split was 1:60 on 2019-09-30.
How did Ocugen, Inc. perform in the last earnings report?
Revenue: $4,055,000 | EPS: -$0.20 | Growth: -23.08%.
Where can I find Ocugen, Inc.'s investor relations reports?
Visit https://www.ocugen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ocugen, Inc.?
You can explore historical data from here
What is the all-time high and low for Ocugen, Inc. stock?
All-time high: $18.77 (2021-02-08) | All-time low: $0.35 (2023-10-26).
What are the key trends affecting Ocugen, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
4 hours ago
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) has granted Rare Pediatric Disease Designation (RPDD) for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations for the treatment of ABCA4-associated retinopathies from the FDA and European Medicines Agency.
seekingalpha.com
18 days ago
Call Start: 8:30 January 1, 0000 8:59 AM ET Ocugen, Inc. (NASDAQ:OCGN ) Q1 2025 - Earnings Conference Call May 9, 2025, 8:00 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Arun Upadhyay - Chief Scientific Office Conference Call Participants Michael Okunewitch - Maxim Group Robert LeBoyer - Noble Swayampakula Ramakanth - H.C. Wainwright Operator Good morning, and welcome to Ocugen's First Quarter 2025 financial results and business update.
globenewswire.com
18 days ago
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026 Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa.
globenewswire.com
25 days ago
MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025.
globenewswire.com
a month ago
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11, 2025.
globenewswire.com
2 months ago
MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy.
globenewswire.com
2 months ago
MALVERN, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU200 clinical trial recently convened and reviewed safety data following dosing of the first cohort in the dose-escalation portion of the Phase 1 study and approved continuation of dosing in the second cohort. OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin, with the potential to treat diabetic macular edema (DME).
seekingalpha.com
3 months ago
Ocugen, Inc. (NASDAQ:OCGN ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Swayampakula Ramakanth - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Daniil Gataulin - Chardan Operator Good morning, and welcome to Ocugen's Fourth Quarter and Full Year 2024 Financial Results and Business Update.
globenewswire.com
3 months ago
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three years Completed dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Data and Safety Monitoring Board (DSMB) recently reviewed interim safety data from Phase 2.
globenewswire.com
3 months ago
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission.
See all news
